ES2084715T3 - ANTIGEN ASSOCIATED WITH URINARY TUMORS, USES OF ANTIGENIC SUBUNITS AND DETECTION PROCEDURES - Google Patents

ANTIGEN ASSOCIATED WITH URINARY TUMORS, USES OF ANTIGENIC SUBUNITS AND DETECTION PROCEDURES

Info

Publication number
ES2084715T3
ES2084715T3 ES90917644T ES90917644T ES2084715T3 ES 2084715 T3 ES2084715 T3 ES 2084715T3 ES 90917644 T ES90917644 T ES 90917644T ES 90917644 T ES90917644 T ES 90917644T ES 2084715 T3 ES2084715 T3 ES 2084715T3
Authority
ES
Spain
Prior art keywords
antigen associated
urinary tumors
detection procedures
methods
antigenic subunits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917644T
Other languages
Spanish (es)
Inventor
Donald L Morton
Rishab K Gupta
David M Euhus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23712351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2084715(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2084715T3 publication Critical patent/ES2084715T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION PRESENTA UN POLIPEPTIDO ANTIGENICO SUSTANCIALMENTE PURIFICADO DE UN ANTIGENO ASOCIADO A TUMORES URINARIOS QUE TIENE, DESPUES DE UNA REDUCCION MEDIANTE BETA-MERCAPTOETANOL Y DE UNA SEPARACION MEDIANTE UNA ELECTROFORESIS DE GELES DE SDS-POLIACRILAMIDA, UN PESO MOLECULAR DE 90 A 100 KD APROXIMADAMENTE. TAMBIEN SE PRESENTAN LOS ANTICUERPOS MONOCLONALES, METODOS PARA DETECTAR CANCERES, METODOS DE INMUNOTERAPIA, METODOS PARA CONTROLAR UNA MALIGNIDAD Y UN METODO PARA DETECTAR UN ANTIGENO ASOCIADO A TUMORES URINARIOS.THE INVENTION INTRODUCES A SUBSTANTIALLY PURIFIED ANTIGENIC POLYPEPTIDE FROM AN ANTIGEN ASSOCIATED WITH URINARY TUMORS THAT IT HAS, AFTER A REDUCTION THROUGH BETA-MERCAPTOETHANOL AND A SEPARATION THROUGH A DEXAIL GELES OF POLIACRES. MONOCLONAL ANTIBODIES, METHODS FOR DETECTING CANCERS, IMMUNOTHERAPY METHODS, METHODS FOR CONTROLLING A MALIGNANCE AND A METHOD FOR DETECTING AN ANTIGEN ASSOCIATED WITH URINARY TUMORS ARE ALSO PRESENTED.

ES90917644T 1989-11-03 1990-10-31 ANTIGEN ASSOCIATED WITH URINARY TUMORS, USES OF ANTIGENIC SUBUNITS AND DETECTION PROCEDURES Expired - Lifetime ES2084715T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43153389A 1989-11-03 1989-11-03

Publications (1)

Publication Number Publication Date
ES2084715T3 true ES2084715T3 (en) 1996-05-16

Family

ID=23712351

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95104918T Expired - Lifetime ES2138102T3 (en) 1989-11-03 1990-10-31 PROCEDURE FOR THE DETECTION OF URINARY ANTIGEN ASSOCIATED WITH TUMORS.
ES90917644T Expired - Lifetime ES2084715T3 (en) 1989-11-03 1990-10-31 ANTIGEN ASSOCIATED WITH URINARY TUMORS, USES OF ANTIGENIC SUBUNITS AND DETECTION PROCEDURES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES95104918T Expired - Lifetime ES2138102T3 (en) 1989-11-03 1990-10-31 PROCEDURE FOR THE DETECTION OF URINARY ANTIGEN ASSOCIATED WITH TUMORS.

Country Status (10)

Country Link
US (2) US5700649A (en)
EP (2) EP0678744B1 (en)
JP (2) JP3423306B2 (en)
AT (2) ATE184704T1 (en)
AU (1) AU661816B2 (en)
CA (2) CA2331088A1 (en)
DE (2) DE69024659T2 (en)
DK (1) DK0498851T3 (en)
ES (2) ES2138102T3 (en)
WO (1) WO1991006866A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044421C (en) * 1990-11-27 2005-06-21 Thomas Hyatt Duffy Squamous cell carcinoma-like immunoreactive antigen from human female urine
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9806104D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP2278024A1 (en) 2000-04-28 2011-01-26 Mannkind Corporation Epitope cluster from NY-ESO-1 for the induction of anti-tumor immunogenicity
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
JP4424987B2 (en) 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Measurement of circulating therapeutic antibodies, antigens and antigen / antibody complexes using an ELISA assay
CA2469738A1 (en) * 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
US20040029135A1 (en) * 2001-12-14 2004-02-12 Ramberg Elliot R. Diagnostic assays for BCWA
AU2003270311A1 (en) * 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
US8557257B2 (en) * 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
EP2049904A1 (en) * 2006-07-28 2009-04-22 Novartis Ag Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma
CA2933579A1 (en) 2013-12-11 2015-06-18 University Of Massachusetts Compositions and methods for treating disease using salmonella t3ss effector protein (sipa)
EP3767629A4 (en) 2018-03-16 2022-01-19 KOTAI Biotechnologies, Inc. Effective clustering of immunological entities

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1603406A (en) * 1977-08-31 1981-11-25 Nat Res Dev Assay of immune complexes
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS5915858A (en) * 1982-07-16 1984-01-26 Otsuka Pharmaceut Co Ltd Measurement of tumor associated antigen peculiar immune composite
US4806628A (en) * 1982-11-30 1989-02-21 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies against melanocytes
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US4562160A (en) * 1983-04-01 1985-12-31 Sloan-Kettering Institute Melanoma tumor antigen and autologous antibody
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4753884A (en) * 1986-01-28 1988-06-28 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
GB2188637B (en) * 1986-02-07 1990-11-14 Oncogen Vaccines against melanoma
US5292636A (en) * 1986-03-31 1994-03-08 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
US4895817A (en) * 1986-05-09 1990-01-23 The Goodyear Tire & Rubber Company Polycondensation catalyst
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5194384A (en) * 1987-04-23 1993-03-16 Bystryn Jean Claude Method for preparing human meloma vaccine
US4946774A (en) * 1987-11-09 1990-08-07 Trustees Of Boston University Process for detecting cancer and for monitoring the effectiveness of cancer therapy
US5250297A (en) * 1989-10-20 1993-10-05 Hybritech Incorporated Tumor-associated antigen, antibodies, compositions and uses therefor
US5427664A (en) * 1993-07-22 1995-06-27 Stoev; Stoyan V. Free solution electrophoresis-membrane filters trapping assay apparatus and method
DE69533295T3 (en) * 1994-02-16 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services Melanoma-associated antigens, epitopes thereof and melanoma-containing vaccines

Also Published As

Publication number Publication date
DE69024659T2 (en) 1996-11-07
AU6875391A (en) 1991-05-31
DE69033295D1 (en) 1999-10-21
ATE132629T1 (en) 1996-01-15
CA2331088A1 (en) 1991-05-04
DE69024659D1 (en) 1996-02-15
EP0678744B1 (en) 1999-09-15
ATE184704T1 (en) 1999-10-15
EP0498851B1 (en) 1996-01-03
EP0678744A2 (en) 1995-10-25
DE69033295T2 (en) 2000-05-25
ES2138102T3 (en) 2000-01-01
DK0498851T3 (en) 1996-05-13
JP2001281255A (en) 2001-10-10
JP3423306B2 (en) 2003-07-07
JPH05505596A (en) 1993-08-19
JP3429281B2 (en) 2003-07-22
EP0678744A3 (en) 1995-12-13
AU661816B2 (en) 1995-08-10
WO1991006866A3 (en) 1991-09-05
CA2072620A1 (en) 1991-05-04
EP0498851A1 (en) 1992-08-19
CA2072620C (en) 2007-06-12
US5700649A (en) 1997-12-23
US5993828A (en) 1999-11-30
WO1991006866A2 (en) 1991-05-16

Similar Documents

Publication Publication Date Title
ES2084715T3 (en) ANTIGEN ASSOCIATED WITH URINARY TUMORS, USES OF ANTIGENIC SUBUNITS AND DETECTION PROCEDURES
FI913560A (en) SYNTHETIC PEPTIDER, SPECIELLT FOER OBSERVATION AV HCV-ANTI-KROPPAR, HCV-INFEKTIONSDIAGNOS OCH DESS FOERHINDRANDE SM VACCIN.
DK1398379T3 (en) Compounds and Methods for Immunotherapy and Diagnosis of Tuberculosis
ES2165851T3 (en) MULTIVALENT PROTEINS THAT JOIN ANTIGENS.
ATE208794T1 (en) HUMANIZED ANTIBODIES
AR094125A2 (en) ANTI IL-12 ISOLATED ANTIBODY
FI893575A (en) ANTIGENSTRUKTURER AV ÇMAJOR HISTOCOMPATIBILITY COMPLEXÇ ANTIGENER AV KLASS I MED SPECIFIKA BAERARMOLEKYLER, FRAMSTAELLNING OCH ANVAENDNING DAERAV.
DK53687D0 (en) PEPTID_ FROM HTLV-III VIRUSH CREATION PROTEIN
HU9300538D0 (en) Method for treating endotoxine shock by means of adhesion inhibiting antibodies
FI950378A0 (en) Immune test for the detection of collagen or collagen fragments
MX9401112A (en) PREPARATION OF PHOTOPROTEIN CONJUGATES AND METHODS TO USE THEM.
ES2196150T3 (en) IMMUNOLOGICAL TOLERANCE INDUCTION BY THE USE OF ANTI-CD4 ANTIBODIES THAT DO NOT INDUCE DEPLOYMENT.
CY1106349T1 (en) HEPATITIS C VIRUS ANTIGEN DETECTION SYSTEMS
DK1374895T3 (en) Pharmaceutical composition of F (AB) 2 fragments of antibodies and method of preparation thereof
NO174153C (en) Antigen and monoclonal antibody for use in vitro, as well as immunological reagents containing them
IL160387A0 (en) Antigen mimotopes and vaccine against cancers
NO305867B1 (en) A method of preparing a monoclonal antibody to Onkostatin M, or a fragment thereof
ES2135480T3 (en) NEW ENDOTHELIAL CELL MOLECULA THAT MEANS THE UNION OF LYMPHOCYTES IN MAN.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 498851

Country of ref document: ES